Pravin Khandare is an experienced global executive with a successful track record of building, transforming and leading procurement organizations for pharma, biotech, medical devices, consumer products, chemicals and industrial companies. Mr. Khandare brings proven capabilities in strategic procurement, category management, supplier relationship management, supplier-enabled innovation, environmental social governance, organizational operating models and operational excellence through procure-to-pay processes, enhanced compliance and controls and improved materials risk management.
Mr. Khandare is a thought leader in the procurement space with insights to enhance procurement capabilities, develop talent, build supplier relationships and mitigate supply risk.
Before joining FTI Consulting, Mr. Khandare was Chief Procurement Officer at Biogen and held various senior leadership positions at Johnson & Johnson (pharmaceuticals and consumer companies). He led procurement and supply chain procurement organizations with a focus on improving performance and creating value.
Prior to Johnson & Johnson, Mr. Khandare held leadership roles at professional services companies such as Silver Oak Solutions/CGI and A.T. Kearney, where he advised several Fortune 50 clients and State governments on operations improvement, strategic sourcing, category management, supplier management, supply risk management and value creation.
- Source-to-pay procurement transformation: Transformed and rebranded procurement by standardizing procurement processes, revamped spend data analytics, centralized category operating model and procurement operations/COEs
- Process Automation: Designed and implemented RPA for six high-value procure-to-pay (P2P) processes to deliver ~5x return on investment (ROI) improving efficiency and effectiveness of the overall P2P process
- Direct materials sourcing: Led sourcing strategy development and execution for 34 categories and sub-categories to deliver $225 million in total value (cost reduction and cost avoidance) and $1.5 billion in supplier-enabled innovation (SEI) while maintaining reliable supply of materials with no supplier-related field actions
- Centralized procurement & category management: Formalized category structure and operationalized strategies for API, biologics and vaccines, and packaging and chemicals categories in collaboration with consumer and medical devices procurement groups to deliver $120 million in total value (cost reduction and cost avoidance) and $500 million in supplier-enabled innovation (SEI)
- Supply risk management: Led supplier risk management effort to enable a standardized approach to supplier due diligence by providing risk-based assessments for risks related to financials, IT security, data privacy and anti-bribery, anti-corruption compliance